



OncoCyte Corporation to Present at the 19th Annual BIO CEO & Investor Conference and the 2017 Disruptive Growth & Healthcare Conference

Feb 13, 2017

ALAMEDA, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th, at 10:30 a.m. ET, where OncoCyte is also being recognized and honored as the Buzz of BIO winner in the "diagnostics and beyond category". OncoCyte will also will also make a company presentation as well as participate in partnering sessions the following day, at the 2017 Disruptive Growth & Healthcare Conference on Wednesday, February 15, 2017, at 2:15 p.m. ET. Both of the conferences will be held in New York, NY.

A live audio and/or webcast and subsequent archived replay of OncoCyte's presentations may be accessed via the Investors section of the Company's website under "Events & Presentations" at <http://investors.oncoocyte.com/>. The replay will be available for 90 days after the event.

About OncoCyte Corporation

OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine ("liquid biopsy") diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients.

While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte's pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte's diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. For more information visit www.oncoocyte.com.

Investor Contact:

EVC Group, Inc.
Michael Polyviou/Doug Sherk
212-850-6020/646-445-4800
mpolyviou@evcgroup.com / dsherk@evcgroup.com

Source: OncoCyte Corporation

